These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 37849737)

  • 1. Targeting the NLRP3 inflammasome and associated cytokines in scleroderma associated interstitial lung disease.
    Woo S; Gandhi S; Ghincea A; Saber T; Lee CJ; Ryu C
    Front Cell Dev Biol; 2023; 11():1254904. PubMed ID: 37849737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
    Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
    Front Immunol; 2020; 11():1990. PubMed ID: 33013852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Altered serum cytokine expression profile in systemic sclerosis and its regulatory mechanisms].
    Zhu HL; DU Q; Chen WL; Zuo XX; Li QZ; Liu SJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Aug; 51(4):716-722. PubMed ID: 31420628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients.
    Schmidt K; Martinez-Gamboa L; Meier S; Witt C; Meisel C; Hanitsch LG; Becker MO; Huscher D; Burmester GR; Riemekasten G
    Arthritis Res Ther; 2009; 11(4):R111. PubMed ID: 19615053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 2 cytokines and scleroderma interstitial lung disease.
    Pellicano C; Vantaggio L; Colalillo A; Pocino K; Basile V; Marino M; Basile U; Rosato E
    Clin Exp Med; 2023 Nov; 23(7):3517-3525. PubMed ID: 37392249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of NLRP3 inflammasome in rituximab-induced interstitial lung disease: a case report.
    Kong H; Wang Y; Zeng X; Zhu Q; Xie W; Dai S
    J Clin Pharm Ther; 2014 Dec; 39(6):691-4. PubMed ID: 25131433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of NLRP3 inflammasome, cytokines and vascular mediators in the skin of systemic sclerosis patients.
    Martínez-Godínez MA; Cruz-Domínguez MP; Jara LJ; Domínguez-López A; Jarillo-Luna RA; Vera-Lastra O; Montes-Cortes DH; Campos-Rodríguez R; López-Sánchez DM; Mejía-Barradas CM; Castelán-Chávez EE; Miliar-García A
    Isr Med Assoc J; 2015 Jan; 17(1):5-10. PubMed ID: 25739168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease.
    Stock CJW; De Lauretis A; Visca D; Daccord C; Kokosi M; Kouranos V; Margaritopoulos G; George PM; Molyneaux PL; Nihtyanova S; Chua F; Maher TM; Ong V; Abraham DJ; Denton CP; Wells AU; Wain LV; Renzoni EA
    Clin Rheumatol; 2020 Apr; 39(4):1173-1179. PubMed ID: 31916109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of NLRP3 inflammasome in systemic sclerosis.
    Lin C; Jiang Z; Cao L; Zou H; Zhu X
    Arthritis Res Ther; 2022 Aug; 24(1):196. PubMed ID: 35974386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis.
    Artlett CM; Sassi-Gaha S; Rieger JL; Boesteanu AC; Feghali-Bostwick CA; Katsikis PD
    Arthritis Rheum; 2011 Nov; 63(11):3563-74. PubMed ID: 21792841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Features and Stages of Pulmonary Fibrosis Driven by Type 2 Inflammation.
    Mattoo H; Bangari DS; Cummings S; Humulock Z; Habiel D; Xu EY; Pate N; Resnick R; Savova V; Qian G; Beil C; Rao E; Nestle FO; Bryce PJ; Subramaniam A
    Am J Respir Cell Mol Biol; 2023 Oct; 69(4):404-421. PubMed ID: 37369139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts.
    Wu M; Baron M; Pedroza C; Salazar GA; Ying J; Charles J; Agarwal SK; Hudson M; Pope J; Zhou X; Reveille JD; Fritzler MJ; Mayes MD; Assassi S
    Arthritis Rheumatol; 2017 Sep; 69(9):1871-1878. PubMed ID: 28575534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of modulatory interaction between cytokines and apoptotic proteins among Scleroderma patients with and without pulmonary involvement.
    Khadilkar P; Chougule D; Tipnis T; Khopkar U; Nadkar M; Rajadhyaksha A; Kini S; Kharkar V; Athvale A; Athvale T; Madkaikar M; Pradhan V
    Cytokine; 2023 Jun; 166():156183. PubMed ID: 37011542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis.
    Hettwer J; Hinterdobler J; Miritsch B; Deutsch MA; Li X; Mauersberger C; Moggio A; Braster Q; Gram H; Robertson AAB; Cooper MA; Groß O; Krane M; Weber C; Koenig W; Soehnlein O; Adamstein NH; Ridker P; Schunkert H; Libby P; Kessler T; Sager HB
    Cardiovasc Res; 2022 Oct; 118(13):2778-2791. PubMed ID: 34718444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Activity of NLRP3 Inflammasome in the Lung of Patients with Anti-Synthetase Syndrome.
    Ramos-Martinez E; Vega-Sánchez AE; Pérez-Rubio G; Mejia M; Buendía-Roldán I; González-Pérez MI; Mateos-Toledo HN; Andrade WA; Falfán-Valencia R; Rojas-Serrano J
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of interleukin-6, total bilirubin, CD3 + CD4 + T cells counts in the acute exacerbation of connective tissue disease-associated interstitial lung disease: a cross-sectional study.
    Ma C; Meng K; Shi S; Zhao T; Chen S; Zhou X; Shu R; Ma M; Tian M; Ding J
    Eur J Med Res; 2023 Sep; 28(1):393. PubMed ID: 37773193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice.
    Khanna D; Lescoat A; Roofeh D; Bernstein EJ; Kazerooni EA; Roth MD; Martinez F; Flaherty KR; Denton CP
    Arthritis Rheumatol; 2022 Jan; 74(1):13-27. PubMed ID: 34313399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NLRP3 inflammasome and NLRP3-related autoinflammatory diseases: From cryopyrin function to targeted therapies.
    Moltrasio C; Romagnuolo M; Marzano AV
    Front Immunol; 2022; 13():1007705. PubMed ID: 36275641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serelaxin inhibits the profibrotic TGF-β1/IL-1β axis by targeting TLR-4 and the NLRP3 inflammasome in cardiac myofibroblasts.
    Cáceres FT; Gaspari TA; Samuel CS; Pinar AA
    FASEB J; 2019 Dec; 33(12):14717-14733. PubMed ID: 31689135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum IL-17 and TNFα as prognostic biomarkers in systemic sclerosis patients: a prospective study.
    Kosałka-Węgiel J; Lichołai S; Pacholczak-Madej R; Dziedzina S; Milewski M; Kuszmiersz P; Korona A; Gąsior J; Matyja-Bednarczyk A; Kwiatkowska H; Zaręba L; Siwiec-Koźlik A; Koźlik-Siwiec P; Wach A; Pociej-Marciak W; Sanak M; Musiał J; Bazan-Socha S; Korkosz M
    Rheumatol Int; 2024 Jan; 44(1):119-128. PubMed ID: 38051374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.